Additional Content Download

Download the Cell and Gene Therapy Manufacturing Agenda to find out more about the speakers, sessions and content.

Pharma IQ spoke to Dr Ryan Guest, Director of Cell Production from cell therapy manufacturer Cellular Therapeutics to explore the raft of emerging trends connected to cell and gene manufacturing.

In this interview Pharma IQ speak to James Sherley to find out what have been the major advancements in using stem cells for toxicology testing and the current challenges that need to be overcome in using stem cells for toxicology. In this interview you will also find out what are going to be the trends in using stem cells for toxicology over the coming 18 months.

Pharma IQ has created an easy-to-digest overview of biomanufacturing activity and spend around the world, whether they are already being implemented or have plans in the near future. You’ll be able to keep it as a handy reference, share it around your colleagues or even stick it on your wall!

When introducing a regenerative medicine cell based product to a commercial setting, there are a number of things to take into consideration to ensure a commercially viable and safe product for patient use. In this Q&A interview, William Fodor, Director of Translational Sciences, Cell Therapy Group, gives some great insights into the commercial manufacturing scale-up process of cell therapies.

One key point of focus for the market is not only the move towards scaling up - manufacturing bigger batches of product- but also scaling out - manufacturing more batches.

In response, to this Pharma IQ spoke to Elena Meurer of apceth GmbH & Co.KG to compile this best practise guide automation scale up –and scale out for cell and
gene therapies.

Magda Papadaki, Head of Manufacturing Innovation, The Association of the British Pharmaceutical Industry (ABPI) shares her presentation from last year's Cell & Gene Therapy Manufacturing Forum: 'Identify the Opportunities and Challenges in Advanced Therapy Manufacturing Process (ATMP)'.

In this presentation:

• Determine what to consider when moving from research to commercial production
• Understand what different set backs will become apparent when looking at cost efficiency of manufacturing 
• Hear the recommended actions that need to be considered when in the positions of discovery and development of advanced therapies